Literature DB >> 12433470

Further probing of the substrate specificities and inhibition of enzymes involved at an early stage of glycosylphosphatidylinositol (GPI) biosynthesis.

Arthur Crossman1, Michael J Paterson, Michael A J Ferguson, Terry K Smith, John S Brimacombe.   

Abstract

1-D-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-1-O-hexadecyl-myo-inositol (14), 1-D-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-myo-inositol 1-(octadecyl phosphate) (18), 1-D-6-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) (24), 1-D-6-O-(2-amino-2-deoxy-alpha-D-mannopyranosyl)-myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) (30) and the corresponding 2-amino-2-deoxy-alpha-D-galactopyranosyl analogue 36 have been prepared and tested in cell-free assays as substrate analogues/inhibitors of alpha-(1 --> 4)-D-mannosyltransferases that are active early on in the glycosylphosphatidylinositol (GPI) biosynthetic pathways of Trypanosoma brucei and HeLa (human) cells. The corresponding N-acetyl derivatives of these compounds were similarly tested as candidate substrate analogues/inhibitors of the N-deacetylases present in both systems. Following on from an early study, 1-L-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-2-O-methyl-myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) (44) was prepared and tested as an inhibitor of the trypanosomal alpha-(1 --> 4)-D-mannosyltransferase. A brief summary of the biological evaluation of the various analogues is provided. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433470     DOI: 10.1016/s0008-6215(02)00187-8

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  5 in total

1.  Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness.

Authors:  Terry K Smith; Arthur Crossman; John S Brimacombe; Michael A J Ferguson
Journal:  EMBO J       Date:  2004-11-04       Impact factor: 11.598

2.  Inhibitors incorporating zinc-binding groups target the GlcNAc-PI de-N-acetylase in Trypanosoma brucei, the causative agent of African sleeping sickness.

Authors:  Nuha Z Abdelwahab; Arthur T Crossman; Lauren Sullivan; Michael A J Ferguson; Michael D Urbaniak
Journal:  Chem Biol Drug Des       Date:  2012-03       Impact factor: 2.817

3.  Discovery of inhibitors of Leishmania β-1,2-mannosyltransferases using a click-chemistry-derived guanosine monophosphate library.

Authors:  Phillip van der Peet; Julie E Ralton; Malcolm J McConville; Spencer J Williams
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

4.  Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase.

Authors:  Michael D Urbaniak; Amy S Capes; Arthur Crossman; Sandra O'Neill; Stephen Thompson; Ian H Gilbert; Michael A J Ferguson
Journal:  Carbohydr Res       Date:  2013-12-30       Impact factor: 2.104

5.  Probing the substrate specificity of Trypanosoma brucei GlcNAc-PI de-N-acetylase with synthetic substrate analogues.

Authors:  Amy S Capes; Arthur Crossman; Michael D Urbaniak; Sophie H Gilbert; Michael A J Ferguson; Ian H Gilbert
Journal:  Org Biomol Chem       Date:  2014-02-12       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.